Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adding Colchicine to Tocilizumab in Hospitalized Patients With Severe COVID-19 Pneumonia: An Open-Label Randomized Controlled Trial

NCT05118737 is registered in ClinicalTrials.gov with Hamad Medical Corporation as lead sponsor.

NCT NCT05118737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05118737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adding Colchicine to Tocilizumab in Hospitalized Patients With Severe COVID-19 Pneumonia: An Open-Label Randomized Controlled Trial
Lead sponsor
Hamad Medical Corporation
Phase
Phase 1
Overall status
Unknown status
Start date
October 1, 2021
Completion date
August 30, 2022
Enrollment
230 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia